Global Mebendazole Market
Global Mebendazole Market

Mebendazole Comprehensive Study by Type (≥98%, ≥99%), End users (Below 2 Years Old, Above 2 Years 5Old), Form (Feed Additives, Tablet, Oral Suspension) Players and Region - Global Market Outlook to 2025

Mebendazole Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Oct 2020 Edition 233 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Mebendazole Market?

Mebendazole is a type of medication which is used for the treatment of parasitic worm infections. The infections include ascariasis, pinworm disease, hookworm infections, guinea worm infections, hydatid disease, and giardia. It prevents newly hatched insect larvae (worms) from growing or multiplying in the body. Moreover, Mebendazole is a white to slightly yellow powder with molecular weight of 295.29. It is less than 0.05% soluble in water, dilute mineral acid solutions, alcohol, but soluble in formic acid. However, it has side effects such as headache, vomiting, and ringing in the ears.

The market study is being classified by Type (≥98% and ≥99%) and major geographies with country level break-up.

Johnson & Johnson (United States), Amneal Pharmaceuticals (United States), Cadila Pharmaceuticals (India), Eipico (Egypt), Esteve Pharmaceuticals (Spain), K A malle (India), Surya (India), GNH India (India), Changzhou Yabang-QH Pharmachem (China) and Aarambh Life Science (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Neha Pharma Private Limited (India), Adani Pharmachem Private Limited (India) and Shanghai Ziqi Biotechnology (China).

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that India Players will contribute to the maximum growth of Global Mebendazole market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Mebendazole market by Type, Application and Region.

On the basis of geography, the market of Mebendazole has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Prevalence of Intestinal Infections is Fuelling the Market
  • Increasing Usage of Mebendazole is Fuelling the Market


Restraints
  • Availability Alternative Options May Hamper the Market
  • Stringent Government Regulations

Opportunities
  • Rising Research and Developments is Boosting the Market

Challenges
  • Side Effects of a Mebendazole





Key Target Audience
Manufacturers, Raw material suppliers, Government associations, Research organizations, Distributors and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • ≥98%
  • ≥99%
By End users
  • Below 2 Years Old
  • Above 2 Years 5Old

By Form
  • Feed Additives
  • Tablet
  • Oral Suspension

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Intestinal Infections is Fuelling the Market
      • 3.2.2. Increasing Usage of Mebendazole is Fuelling the Market
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of a Mebendazole
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mebendazole, by Type, End users, Form and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Mebendazole (Value)
      • 5.2.1. Global Mebendazole by: Type (Value)
        • 5.2.1.1. ≥98%
        • 5.2.1.2. ≥99%
      • 5.2.2. Global Mebendazole by: End users (Value)
        • 5.2.2.1. Below 2 Years Old
        • 5.2.2.2. Above 2 Years 5Old
      • 5.2.3. Global Mebendazole by: Form (Value)
        • 5.2.3.1. Feed Additives
        • 5.2.3.2. Tablet
        • 5.2.3.3. Oral Suspension
      • 5.2.4. Global Mebendazole Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Mebendazole: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amneal Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cadila Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eipico (Egypt)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Esteve Pharmaceuticals (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. K A malle (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Surya (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GNH India (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Changzhou Yabang-QH Pharmachem (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aarambh Life Science (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mebendazole Sale, by Type, End users, Form and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Mebendazole (Value)
      • 7.2.1. Global Mebendazole by: Type (Value)
        • 7.2.1.1. ≥98%
        • 7.2.1.2. ≥99%
      • 7.2.2. Global Mebendazole by: End users (Value)
        • 7.2.2.1. Below 2 Years Old
        • 7.2.2.2. Above 2 Years 5Old
      • 7.2.3. Global Mebendazole by: Form (Value)
        • 7.2.3.1. Feed Additives
        • 7.2.3.2. Tablet
        • 7.2.3.3. Oral Suspension
      • 7.2.4. Global Mebendazole Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mebendazole: by Type(USD Million)
  • Table 2. Mebendazole ≥98% , by Region USD Million (2014-2019)
  • Table 3. Mebendazole ≥99% , by Region USD Million (2014-2019)
  • Table 4. Mebendazole: by End users(USD Million)
  • Table 5. Mebendazole Below 2 Years Old , by Region USD Million (2014-2019)
  • Table 6. Mebendazole Above 2 Years 5Old , by Region USD Million (2014-2019)
  • Table 7. Mebendazole: by Form(USD Million)
  • Table 8. Mebendazole Feed Additives , by Region USD Million (2014-2019)
  • Table 9. Mebendazole Tablet , by Region USD Million (2014-2019)
  • Table 10. Mebendazole Oral Suspension , by Region USD Million (2014-2019)
  • Table 11. South America Mebendazole, by Country USD Million (2014-2019)
  • Table 12. South America Mebendazole, by Type USD Million (2014-2019)
  • Table 13. South America Mebendazole, by End users USD Million (2014-2019)
  • Table 14. South America Mebendazole, by Form USD Million (2014-2019)
  • Table 15. Brazil Mebendazole, by Type USD Million (2014-2019)
  • Table 16. Brazil Mebendazole, by End users USD Million (2014-2019)
  • Table 17. Brazil Mebendazole, by Form USD Million (2014-2019)
  • Table 18. Argentina Mebendazole, by Type USD Million (2014-2019)
  • Table 19. Argentina Mebendazole, by End users USD Million (2014-2019)
  • Table 20. Argentina Mebendazole, by Form USD Million (2014-2019)
  • Table 21. Rest of South America Mebendazole, by Type USD Million (2014-2019)
  • Table 22. Rest of South America Mebendazole, by End users USD Million (2014-2019)
  • Table 23. Rest of South America Mebendazole, by Form USD Million (2014-2019)
  • Table 24. Asia Pacific Mebendazole, by Country USD Million (2014-2019)
  • Table 25. Asia Pacific Mebendazole, by Type USD Million (2014-2019)
  • Table 26. Asia Pacific Mebendazole, by End users USD Million (2014-2019)
  • Table 27. Asia Pacific Mebendazole, by Form USD Million (2014-2019)
  • Table 28. China Mebendazole, by Type USD Million (2014-2019)
  • Table 29. China Mebendazole, by End users USD Million (2014-2019)
  • Table 30. China Mebendazole, by Form USD Million (2014-2019)
  • Table 31. Japan Mebendazole, by Type USD Million (2014-2019)
  • Table 32. Japan Mebendazole, by End users USD Million (2014-2019)
  • Table 33. Japan Mebendazole, by Form USD Million (2014-2019)
  • Table 34. India Mebendazole, by Type USD Million (2014-2019)
  • Table 35. India Mebendazole, by End users USD Million (2014-2019)
  • Table 36. India Mebendazole, by Form USD Million (2014-2019)
  • Table 37. South Korea Mebendazole, by Type USD Million (2014-2019)
  • Table 38. South Korea Mebendazole, by End users USD Million (2014-2019)
  • Table 39. South Korea Mebendazole, by Form USD Million (2014-2019)
  • Table 40. Taiwan Mebendazole, by Type USD Million (2014-2019)
  • Table 41. Taiwan Mebendazole, by End users USD Million (2014-2019)
  • Table 42. Taiwan Mebendazole, by Form USD Million (2014-2019)
  • Table 43. Australia Mebendazole, by Type USD Million (2014-2019)
  • Table 44. Australia Mebendazole, by End users USD Million (2014-2019)
  • Table 45. Australia Mebendazole, by Form USD Million (2014-2019)
  • Table 46. Rest of Asia-Pacific Mebendazole, by Type USD Million (2014-2019)
  • Table 47. Rest of Asia-Pacific Mebendazole, by End users USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Mebendazole, by Form USD Million (2014-2019)
  • Table 49. Europe Mebendazole, by Country USD Million (2014-2019)
  • Table 50. Europe Mebendazole, by Type USD Million (2014-2019)
  • Table 51. Europe Mebendazole, by End users USD Million (2014-2019)
  • Table 52. Europe Mebendazole, by Form USD Million (2014-2019)
  • Table 53. Germany Mebendazole, by Type USD Million (2014-2019)
  • Table 54. Germany Mebendazole, by End users USD Million (2014-2019)
  • Table 55. Germany Mebendazole, by Form USD Million (2014-2019)
  • Table 56. France Mebendazole, by Type USD Million (2014-2019)
  • Table 57. France Mebendazole, by End users USD Million (2014-2019)
  • Table 58. France Mebendazole, by Form USD Million (2014-2019)
  • Table 59. Italy Mebendazole, by Type USD Million (2014-2019)
  • Table 60. Italy Mebendazole, by End users USD Million (2014-2019)
  • Table 61. Italy Mebendazole, by Form USD Million (2014-2019)
  • Table 62. United Kingdom Mebendazole, by Type USD Million (2014-2019)
  • Table 63. United Kingdom Mebendazole, by End users USD Million (2014-2019)
  • Table 64. United Kingdom Mebendazole, by Form USD Million (2014-2019)
  • Table 65. Netherlands Mebendazole, by Type USD Million (2014-2019)
  • Table 66. Netherlands Mebendazole, by End users USD Million (2014-2019)
  • Table 67. Netherlands Mebendazole, by Form USD Million (2014-2019)
  • Table 68. Rest of Europe Mebendazole, by Type USD Million (2014-2019)
  • Table 69. Rest of Europe Mebendazole, by End users USD Million (2014-2019)
  • Table 70. Rest of Europe Mebendazole, by Form USD Million (2014-2019)
  • Table 71. MEA Mebendazole, by Country USD Million (2014-2019)
  • Table 72. MEA Mebendazole, by Type USD Million (2014-2019)
  • Table 73. MEA Mebendazole, by End users USD Million (2014-2019)
  • Table 74. MEA Mebendazole, by Form USD Million (2014-2019)
  • Table 75. Middle East Mebendazole, by Type USD Million (2014-2019)
  • Table 76. Middle East Mebendazole, by End users USD Million (2014-2019)
  • Table 77. Middle East Mebendazole, by Form USD Million (2014-2019)
  • Table 78. Africa Mebendazole, by Type USD Million (2014-2019)
  • Table 79. Africa Mebendazole, by End users USD Million (2014-2019)
  • Table 80. Africa Mebendazole, by Form USD Million (2014-2019)
  • Table 81. North America Mebendazole, by Country USD Million (2014-2019)
  • Table 82. North America Mebendazole, by Type USD Million (2014-2019)
  • Table 83. North America Mebendazole, by End users USD Million (2014-2019)
  • Table 84. North America Mebendazole, by Form USD Million (2014-2019)
  • Table 85. United States Mebendazole, by Type USD Million (2014-2019)
  • Table 86. United States Mebendazole, by End users USD Million (2014-2019)
  • Table 87. United States Mebendazole, by Form USD Million (2014-2019)
  • Table 88. Canada Mebendazole, by Type USD Million (2014-2019)
  • Table 89. Canada Mebendazole, by End users USD Million (2014-2019)
  • Table 90. Canada Mebendazole, by Form USD Million (2014-2019)
  • Table 91. Mexico Mebendazole, by Type USD Million (2014-2019)
  • Table 92. Mexico Mebendazole, by End users USD Million (2014-2019)
  • Table 93. Mexico Mebendazole, by Form USD Million (2014-2019)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Mebendazole: by Type(USD Million)
  • Table 105. Mebendazole ≥98% , by Region USD Million (2020-2025)
  • Table 106. Mebendazole ≥99% , by Region USD Million (2020-2025)
  • Table 107. Mebendazole: by End users(USD Million)
  • Table 108. Mebendazole Below 2 Years Old , by Region USD Million (2020-2025)
  • Table 109. Mebendazole Above 2 Years 5Old , by Region USD Million (2020-2025)
  • Table 110. Mebendazole: by Form(USD Million)
  • Table 111. Mebendazole Feed Additives , by Region USD Million (2020-2025)
  • Table 112. Mebendazole Tablet , by Region USD Million (2020-2025)
  • Table 113. Mebendazole Oral Suspension , by Region USD Million (2020-2025)
  • Table 114. South America Mebendazole, by Country USD Million (2020-2025)
  • Table 115. South America Mebendazole, by Type USD Million (2020-2025)
  • Table 116. South America Mebendazole, by End users USD Million (2020-2025)
  • Table 117. South America Mebendazole, by Form USD Million (2020-2025)
  • Table 118. Brazil Mebendazole, by Type USD Million (2020-2025)
  • Table 119. Brazil Mebendazole, by End users USD Million (2020-2025)
  • Table 120. Brazil Mebendazole, by Form USD Million (2020-2025)
  • Table 121. Argentina Mebendazole, by Type USD Million (2020-2025)
  • Table 122. Argentina Mebendazole, by End users USD Million (2020-2025)
  • Table 123. Argentina Mebendazole, by Form USD Million (2020-2025)
  • Table 124. Rest of South America Mebendazole, by Type USD Million (2020-2025)
  • Table 125. Rest of South America Mebendazole, by End users USD Million (2020-2025)
  • Table 126. Rest of South America Mebendazole, by Form USD Million (2020-2025)
  • Table 127. Asia Pacific Mebendazole, by Country USD Million (2020-2025)
  • Table 128. Asia Pacific Mebendazole, by Type USD Million (2020-2025)
  • Table 129. Asia Pacific Mebendazole, by End users USD Million (2020-2025)
  • Table 130. Asia Pacific Mebendazole, by Form USD Million (2020-2025)
  • Table 131. China Mebendazole, by Type USD Million (2020-2025)
  • Table 132. China Mebendazole, by End users USD Million (2020-2025)
  • Table 133. China Mebendazole, by Form USD Million (2020-2025)
  • Table 134. Japan Mebendazole, by Type USD Million (2020-2025)
  • Table 135. Japan Mebendazole, by End users USD Million (2020-2025)
  • Table 136. Japan Mebendazole, by Form USD Million (2020-2025)
  • Table 137. India Mebendazole, by Type USD Million (2020-2025)
  • Table 138. India Mebendazole, by End users USD Million (2020-2025)
  • Table 139. India Mebendazole, by Form USD Million (2020-2025)
  • Table 140. South Korea Mebendazole, by Type USD Million (2020-2025)
  • Table 141. South Korea Mebendazole, by End users USD Million (2020-2025)
  • Table 142. South Korea Mebendazole, by Form USD Million (2020-2025)
  • Table 143. Taiwan Mebendazole, by Type USD Million (2020-2025)
  • Table 144. Taiwan Mebendazole, by End users USD Million (2020-2025)
  • Table 145. Taiwan Mebendazole, by Form USD Million (2020-2025)
  • Table 146. Australia Mebendazole, by Type USD Million (2020-2025)
  • Table 147. Australia Mebendazole, by End users USD Million (2020-2025)
  • Table 148. Australia Mebendazole, by Form USD Million (2020-2025)
  • Table 149. Rest of Asia-Pacific Mebendazole, by Type USD Million (2020-2025)
  • Table 150. Rest of Asia-Pacific Mebendazole, by End users USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Mebendazole, by Form USD Million (2020-2025)
  • Table 152. Europe Mebendazole, by Country USD Million (2020-2025)
  • Table 153. Europe Mebendazole, by Type USD Million (2020-2025)
  • Table 154. Europe Mebendazole, by End users USD Million (2020-2025)
  • Table 155. Europe Mebendazole, by Form USD Million (2020-2025)
  • Table 156. Germany Mebendazole, by Type USD Million (2020-2025)
  • Table 157. Germany Mebendazole, by End users USD Million (2020-2025)
  • Table 158. Germany Mebendazole, by Form USD Million (2020-2025)
  • Table 159. France Mebendazole, by Type USD Million (2020-2025)
  • Table 160. France Mebendazole, by End users USD Million (2020-2025)
  • Table 161. France Mebendazole, by Form USD Million (2020-2025)
  • Table 162. Italy Mebendazole, by Type USD Million (2020-2025)
  • Table 163. Italy Mebendazole, by End users USD Million (2020-2025)
  • Table 164. Italy Mebendazole, by Form USD Million (2020-2025)
  • Table 165. United Kingdom Mebendazole, by Type USD Million (2020-2025)
  • Table 166. United Kingdom Mebendazole, by End users USD Million (2020-2025)
  • Table 167. United Kingdom Mebendazole, by Form USD Million (2020-2025)
  • Table 168. Netherlands Mebendazole, by Type USD Million (2020-2025)
  • Table 169. Netherlands Mebendazole, by End users USD Million (2020-2025)
  • Table 170. Netherlands Mebendazole, by Form USD Million (2020-2025)
  • Table 171. Rest of Europe Mebendazole, by Type USD Million (2020-2025)
  • Table 172. Rest of Europe Mebendazole, by End users USD Million (2020-2025)
  • Table 173. Rest of Europe Mebendazole, by Form USD Million (2020-2025)
  • Table 174. MEA Mebendazole, by Country USD Million (2020-2025)
  • Table 175. MEA Mebendazole, by Type USD Million (2020-2025)
  • Table 176. MEA Mebendazole, by End users USD Million (2020-2025)
  • Table 177. MEA Mebendazole, by Form USD Million (2020-2025)
  • Table 178. Middle East Mebendazole, by Type USD Million (2020-2025)
  • Table 179. Middle East Mebendazole, by End users USD Million (2020-2025)
  • Table 180. Middle East Mebendazole, by Form USD Million (2020-2025)
  • Table 181. Africa Mebendazole, by Type USD Million (2020-2025)
  • Table 182. Africa Mebendazole, by End users USD Million (2020-2025)
  • Table 183. Africa Mebendazole, by Form USD Million (2020-2025)
  • Table 184. North America Mebendazole, by Country USD Million (2020-2025)
  • Table 185. North America Mebendazole, by Type USD Million (2020-2025)
  • Table 186. North America Mebendazole, by End users USD Million (2020-2025)
  • Table 187. North America Mebendazole, by Form USD Million (2020-2025)
  • Table 188. United States Mebendazole, by Type USD Million (2020-2025)
  • Table 189. United States Mebendazole, by End users USD Million (2020-2025)
  • Table 190. United States Mebendazole, by Form USD Million (2020-2025)
  • Table 191. Canada Mebendazole, by Type USD Million (2020-2025)
  • Table 192. Canada Mebendazole, by End users USD Million (2020-2025)
  • Table 193. Canada Mebendazole, by Form USD Million (2020-2025)
  • Table 194. Mexico Mebendazole, by Type USD Million (2020-2025)
  • Table 195. Mexico Mebendazole, by End users USD Million (2020-2025)
  • Table 196. Mexico Mebendazole, by Form USD Million (2020-2025)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mebendazole: by Type USD Million (2014-2019)
  • Figure 5. Global Mebendazole: by End users USD Million (2014-2019)
  • Figure 6. Global Mebendazole: by Form USD Million (2014-2019)
  • Figure 7. South America Mebendazole Share (%), by Country
  • Figure 8. Asia Pacific Mebendazole Share (%), by Country
  • Figure 9. Europe Mebendazole Share (%), by Country
  • Figure 10. MEA Mebendazole Share (%), by Country
  • Figure 11. North America Mebendazole Share (%), by Country
  • Figure 12. Global Mebendazole share by Players 2019 (%)
  • Figure 13. Global Mebendazole share by Players (Top 3) 2019(%)
  • Figure 14. Global Mebendazole share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 17. Johnson & Johnson (United States) Revenue: by Geography 2019
  • Figure 18. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amneal Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 20. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 21. Cadila Pharmaceuticals (India) Revenue: by Geography 2019
  • Figure 22. Eipico (Egypt) Revenue, Net Income and Gross profit
  • Figure 23. Eipico (Egypt) Revenue: by Geography 2019
  • Figure 24. Esteve Pharmaceuticals (Spain) Revenue, Net Income and Gross profit
  • Figure 25. Esteve Pharmaceuticals (Spain) Revenue: by Geography 2019
  • Figure 26. K A malle (India) Revenue, Net Income and Gross profit
  • Figure 27. K A malle (India) Revenue: by Geography 2019
  • Figure 28. Surya (India) Revenue, Net Income and Gross profit
  • Figure 29. Surya (India) Revenue: by Geography 2019
  • Figure 30. GNH India (India) Revenue, Net Income and Gross profit
  • Figure 31. GNH India (India) Revenue: by Geography 2019
  • Figure 32. Changzhou Yabang-QH Pharmachem (China) Revenue, Net Income and Gross profit
  • Figure 33. Changzhou Yabang-QH Pharmachem (China) Revenue: by Geography 2019
  • Figure 34. Aarambh Life Science (India) Revenue, Net Income and Gross profit
  • Figure 35. Aarambh Life Science (India) Revenue: by Geography 2019
  • Figure 36. Global Mebendazole: by Type USD Million (2020-2025)
  • Figure 37. Global Mebendazole: by End users USD Million (2020-2025)
  • Figure 38. Global Mebendazole: by Form USD Million (2020-2025)
  • Figure 39. South America Mebendazole Share (%), by Country
  • Figure 40. Asia Pacific Mebendazole Share (%), by Country
  • Figure 41. Europe Mebendazole Share (%), by Country
  • Figure 42. MEA Mebendazole Share (%), by Country
  • Figure 43. North America Mebendazole Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Johnson & Johnson (United States)
  • Amneal Pharmaceuticals (United States)
  • Cadila Pharmaceuticals (India)
  • Eipico (Egypt)
  • Esteve Pharmaceuticals (Spain)
  • K A malle (India)
  • Surya (India)
  • GNH India (India)
  • Changzhou Yabang-QH Pharmachem (China)
  • Aarambh Life Science (India)
Additional players considered in the study are as follows:
Neha Pharma Private Limited (India) , Adani Pharmachem Private Limited (India) , Shanghai Ziqi Biotechnology (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation